RLY 4008 is a potent and highly selective FGFR2 inhibitor which demonstrates a strong activity against primary and acquired FGFR2 resistance mutations in cellular assays, and potent antiproliferative effects on FGFR2-altered human tumor cell lines. The gene discussed is FGFR2; the disease is neoplasm.